Former pharma executive Alex Azar has a new title: secretary of Health and Human Services.
The Senate voted 55-43 to confirm the nomination of Azar, the former head of pharmaceutical giant Eli Lilly’s U.S. operations, to serve in the role vacated by Tom Price, M.D.
Price, a former congressman, resigned in September after eight months on the job due to controversy over use of private planes for government travel using taxpayer money. President Donald Trump soon tapped Azar to fill the role, saying he would be “a star for better healthcare and lower drug prices!”
Azar has unique qualifications because he has already worked at HHS. He served as general counsel for the department from 2001 to 2005 and then became the deputy secretary under then-HHS Secretary Mike Leavitt, a position he held for two years.
But not everyone was convinced. Many Democrats opposed his nomination from the beginning, noting his ties to the pharmaceutical industry and questioning whether he would be committed to lowering drug prices. The skyrocketing cost of prescription drugs came up frequently during the course of his confirmation hearings during the Senate vote on Tuesday to advance his nomination.
On the Senate floor today, several Democrats, including Ron Wyden, D-Ore., ranking member of the Senate Finance Committee, Patty Murray, D-Wash., and Chris Murphy, D-Conn., said they would vote against his nomination. In addition to their concerns that drug prices rose under Azar’s watch while he was at Eli Lilly, they also fear he will work with the Trump administration to sabotage the Affordable Care Act.
But Senate Majority Leader Mitch McConnell, R-Ky., praised Azar, whom he called the “right man for the job.”
“In his impressive testimony before the Finance Committee, Mr. Azar discussed his intention to confront head-on the opioid crisis that is hurting so many families across the country, including in my home state of Kentucky. He made clear that he will place an important priority on prevention, education and enforcement to halt the advance of this scourge,” McConnell said.
As the head of HHS, Azar will be responsible for overseeing $1.13 trillion in department spending and supervising research and administering health programs, including Medicare and Medicaid.
By Ilene MacDonald
Source: Fierce Healthcare
With a first to market advantage, Ferring’s Rebyota has seen early positive adoption from gastroenterologists and infectious disease specialist in the first month post-launch. As part of their Launch Dynamix™: C.diff service, Spherix reports, while new monthly initiations are modest, a majority of physicians trialing Rebyota report high satisfaction.
Global biopharmaceutical firm UCB has entered an early drug discovery collaboration with Aitia. The collaboration is aimed at discovering and validating new drug targets and drug candidates that are linked to clinical endpoints causally in Huntington’s disease, a debilitating genetic disorder.
Foundry Innovation & Research 1—known by its much catchier acronym, FIRE1—announced Wednesday the close of a $25 million financing round. It was led by a pair of new investors in the company: Andera Partners and Novo Holdings, the holding and investment company that serves as the controlling shareholder for Novo Nordisk and Novozymes.
